IGM Biosciences Inc (IGMS) — Financial Flexibility Index

Latest as of June 2025: -8.38x

IGM Biosciences Inc (IGMS) has a Financial Flexibility Index of -8.38x as of June 2025. Free cash flow of $-50.79 Million (operating CF $-50.79 Million minus capex $1.00K) represents -8% of total liabilities ($6.06 Million). Check IGM Biosciences Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Financial Flexibility Index

-8.38x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-50.79 Million
Operating CF − Capex

Total Liabilities

$6.06 Million
USD

Capital Expenditures

$1.00K
USD

IGM Biosciences Inc Financial Flexibility Index (2017–2024)

Historical Financial Flexibility Index trend for IGM Biosciences Inc across 8 annual periods. See IGM Biosciences Inc (IGMS) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for IGM Biosciences Inc (2017–2024)

Year-by-year free cash flow to debt coverage for IGM Biosciences Inc. For the full company profile including market capitalisation, see IGMS market cap overview.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2024 -0.68x $-147.14 Million $-153.00 Million $217.54 Million ▲ +17.2%
2023 -0.82x $-179.85 Million $-192.23 Million $220.18 Million ▼ -4345.3%
2022 0.02x $4.35 Million $-5.85 Million $226.24 Million ▲ +100.9%
2021 -2.09x $-111.09 Million $-124.34 Million $53.22 Million ▼ -12.4%
2020 -1.86x $-49.80 Million $-67.30 Million $26.82 Million ▲ +8.3%
2019 -2.03x $-42.78 Million $-45.12 Million $21.12 Million ▼ -634.3%
2018 -0.28x $-19.26 Million $-20.04 Million $69.81 Million ▼ -15.9%
2017 -0.24x $-9.97 Million $-10.36 Million $41.89 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities